HLHongtao Liu
Hongtao Liu
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongtao Liu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Allen Y. Hong
Department of Synthetic Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
2 shared publications Bernard P. Murray
Department of Drug Metabolism, Gilead Sciences, Foster City, CA, USA
2 shared publications- Christian Callebaut
Clinical Virology, Gilead Sciences, Inc., 333 Lakeside Dr, Foster City, 94404 CA, USA
2 shared publications Gerry R. Rhodes
Department of Drug Metabolism, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94303, USA
2 shared publications- Lianhong Xu
Department of Medicinal Chemistry, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94303, USA
2 shared publications Luong K. Tsai
Department of Biology, Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94303, USA
2 shared publications
Latest Publications
- 1 February 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (3) , 989-994
Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region
- 1 February 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (3) , 989-994
Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: Core region
- 30 April 2010
- Published by Elsevier in Antiviral Research
- Vol. 86 (1) , A31
Biological Profiling of GS-9350, a Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects In Vitro
- 30 April 2010
- Published by Elsevier in Antiviral Research
- Vol. 86 (1) , A31
Biological Profiling of GS-9350, a Novel Pharmacoenhancer that Lacks Anti-HIV Activity and Exhibits Low Potential for Metabolic Adverse Effects In Vitro